A Phase II Open-Label, Multicenter, Non Randomized Study Evaluating the Efficacy and the Safety of Clofarabine in Combination With IV Busulfan and Thymoglobulin (CBT) as a Reduced Intensity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Adult Patients With High-Risk AML, MDS or ALL.

Trial Profile

A Phase II Open-Label, Multicenter, Non Randomized Study Evaluating the Efficacy and the Safety of Clofarabine in Combination With IV Busulfan and Thymoglobulin (CBT) as a Reduced Intensity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Adult Patients With High-Risk AML, MDS or ALL.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Clofarabine (Primary) ; Antithymocyte globulin; Busulfan; Ciclosporin
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms Cloric
  • Most Recent Events

    • 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Dec 2010 Planned End Date changed from 1 Oct 2011 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 04 May 2010 Actual initiation date (Oct 2011), lead trial investigators added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top